Moreover, small molecules targeting α-synuclein oligomerization (NPT100-18A, NPT100-14A, and ELN48228) were described to revert the degenerative phenotype under both basal and induced stress conditions in iPSC-DA neurons harbouring the p.A53T mutation (Figure 4), indicating a treatment strategy for PD and other synucleinopathies [65]. The gene discussed is SNCA; the disease is Parkinson disease.